{"nctId":"NCT02035267","briefTitle":"Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat","startDateStruct":{"date":"2014-01"},"conditions":["Moderate to Severe Convexity of Submental Fat","Safety","Efficacy"],"count":93,"armGroups":[{"label":"Placebo - Grade 1","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"ATX-101 deoxycholic acid injection - Grade 1","type":"EXPERIMENTAL","interventionNames":["Drug: Deoxycholic Acid"]},{"label":"Placebo - Grade 4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"ATX-101 deoxycholic acid injection - Grade 4","type":"EXPERIMENTAL","interventionNames":["Drug: Deoxycholic Acid"]}],"interventions":[{"name":"Deoxycholic Acid","otherNames":["ATX-101 deoxycholic acid injection"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects, 18 to 65 years old\n* Stable Body weight\n* Body Mass Index (BMI) of ≤40.0 kg/m\\^2\n* Acceptable volume of submental fat graded by clinician\n* Dissatisfaction with the submental area expressed by the subject\n* Signed informed consent form (ICF)\n* SMF ratings of 1 or 4\n\nExclusion Criteria:\n\n* No prior intervention for submental fat (SMF) (eg, liposuction, surgery, or lipolytic agents)\n* Presence of clinically significant health problems\n* History of trauma associated with the chin or neck areas that in the judgment of the investigator may affect evaluation of safety or efficacy of treatment\n* Body mass index ≤40 kg/m\\^2","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments","description":"The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).\n\nThe participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.3","spread":null},{"groupId":"OG001","value":"6.7","spread":null},{"groupId":"OG002","value":"89.3","spread":null},{"groupId":"OG003","value":"13.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Both the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and Patient-Reported Submental Fat Rating Scale (PR-SMFRS) Assessments","description":"The investigator evaluated the participant's chin and neck area using the Clinician-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).\n\nThe participant evaluated their chin and neck area using the Patient-Reported Submental Fat Rating Scale (a 5-point scale) where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)","description":"The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":null},{"groupId":"OG001","value":"20.0","spread":null},{"groupId":"OG002","value":"96.4","spread":null},{"groupId":"OG003","value":"26.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS)","description":"The investigator evaluated the participant's chin and neck area using the CR-SMFRS 5-point scale where: 0=absent submental convexity (best) to 4= extreme submental convexity (worst).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"13.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least a 1-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Patient-Reported Submental Fat Rating Scale (PR-SMFRS)","description":"The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.7","spread":null},{"groupId":"OG001","value":"33.3","spread":null},{"groupId":"OG002","value":"89.3","spread":null},{"groupId":"OG003","value":"46.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With at Least a 2-Grade Reduction (Improvement) at 12 Weeks From Last Treatment Based on Patient-Reported Submental Fat Rating Scale (PR-SMFRS)","description":"The participant evaluated their chin and neck area using the PR-SMFRS 5-point scale where: 0=no chin fat at all (best) to 4= a very large amount of chin fat (worst).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.7","spread":null},{"groupId":"OG001","value":"20.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Change From Baseline in Submental Skin Laxity Grade Scale (SMSLG)","description":"The SMSLG is an integration of three features: skin wrinkling, adherence to underlying neck structures (bone and muscle) and redundancy (horizontal and vertical folds). Each grade (1=none, 2=mild, 3=moderate and 4=severe) defines the maximal allowed limit for skin wrinkling, adherence to underlying structures and redundancy.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.60"},{"groupId":"OG001","value":"-0.1","spread":"0.35"},{"groupId":"OG002","value":"-0.3","spread":"0.55"},{"groupId":"OG003","value":"-0.2","spread":"0.56"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":31},"commonTop":["Injection site pain","Injection site bruising","Injection site oedema","Injection site anaesthesia","Injection site swelling"]}}}